Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 1.00 |
| ▸ | SELL | P14151 | 2/20 | 0.54 |
| ▸ | SELP | P16109 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | RECQL | P46063 | 3/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | FASN | P49327 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | FUT7 | Q11130 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Exifone SCHEMBL29375026 | 1.00 | HDAC1 (1.00) | HDAC1SELLSELPKDM4EALDH1A1 | |
| Exifone SCHEMBL27795679 | 0.98 | HDAC1 (0.96) | HDAC1SELLSELPKDM4EALDH1A1 | |
| SCHEMBL6847401 | 0.91 | HDAC1 (0.84) | HDAC1SELLSELPKDM4EALDH1A1 | |
| SCHEMBL30669853 | 0.91 | HDAC1 (0.84) | HDAC1SELLSELPKDM4EALDH1A1 | |
| Exifone SCHEMBL18993025 | 0.89 | HDAC1 (0.80) | HDAC1SELLSELPKDM4EALDH1A1 | |
| SCHEMBL19003430 | 0.89 | HDAC1 (0.79) | HDAC1SELLSELPKDM4EALDH1A1 | |
| SCHEMBL19763340 | 0.86 | HDAC1 (0.76) | HDAC1SELLSELPKDM4EALDH1A1 | |
| SCHEMBL19003428 | 0.86 | HDAC1 (0.76) | HDAC1SELLSELPKDM4EALDH1A1 | |
| SCHEMBL5703332 | 0.86 | HDAC1 (0.75) | HDAC1SELLSELPKDM4EALDH1A1 | |
| SCHEMBL30595472 | 0.86 | HDAC1 (0.75) | HDAC1SELLSELPKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1600 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4525870-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | Corcept Therapeutics Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-07-25 | — | — | US | claimed |
| CN-112731765-B | Fluorine-containing resin composition, preparation method thereof and preparation method of cured film containing fluorine-containing resin composition | 西安瑞联新材料股份有限公司 | 2024-03-26 | — | — | CN | claimed |
| EP-4317576-A1 | FIBER-TREATING AGENT | Kao Corporation (JP) | 2024-02-07 | — | — | EP | claimed |
| US-20230372312-A1 | Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-11-23 | — | — | US | claimed |
| WO-2023225282-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-11-23 | — | — | WO | claimed |
| US-20230194984-A1 | FLUORINE-CONTAINING RESIN COMPOSITION AND PREPARATION METHOD THEREOF, AND PREPARATION METHOD OF CURED FILM CONTAINING SAME | XI'AN MANARECO NEW MATERIALS CO., LTD. (CN) | 2023-06-22 | — | — | US | claimed |
| EP-4193221-A1 | SOLUBLE POLYIMIDES AND DIIMIDES FOR SPIN-ON CARBON APPLICATIONS | Brewer Science Inc. (US) | 2023-06-14 | — | — | EP | claimed |
| CN-116018380-A | Soluble polyimides and imides for spin-on carbon applications | 布鲁尔科技公司 | 2023-04-25 | — | — | CN | claimed |
| WO-2022210993-A1 | FIBER-TREATING AGENT | 花王株式会社 | 2022-10-06 | — | — | WO | claimed |
| EP-0651893-A1 | HEXAHYDROXYBENZOPHENONE SULFONATE ESTERS OF DIAZONAPHTHOQUINONE SENSITIZERS AND POSITIVE PHOTORESISTS EMPLOYING SAME | HOECHST CELANESE CORPORATION (US) | 1995-05-10 | — | — | EP | claimed |
| US-5395728-A | Containing alkali soluble novolak resin; improved heat resistance without sacrificing other propertes | CLARIANT FINANCE (BVI) LIMITED (VG) | 1995-03-07 | — | — | US | claimed |
| US-5294521-A | Forming patterns on semiconductor wafers | HOECHST CELANESE CORPORATION (US) | 1994-03-15 | — | — | US | claimed |
| WO-1994002885-A1 | HEXAHYDROXYBENZOPHENONE SULFONATE ESTERS OF DIAZONAPHTHOQUINONE SENSITIZERS AND POSITIVE PHOTORESISTS EMPLOYING SAME | HOECHST CELANESE CORPORATION (US) | 1994-02-03 | — | — | WO | claimed |
| US-5283324-A | Reacting phenol compound and quinone diazide sulfonyl halide in solvent mixtures of different dielectric constants | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1994-02-01 | — | — | US | claimed |
| US-5206348-A | Thermostability, high speed, heat resistance | MORTON INTERNATIONAL, INC. (US) | 1993-04-27 | — | — | US | claimed |
| EP-0275970-B1 | POSITIVE-WORKING PHOTORESIST COMPOSITION | FUJI PHOTO FILM CO., LTD. (JP) | 1993-03-24 | — | — | EP | claimed |
| EP-0315964-B1 | A NOVEL PHARMACEUTICAL COMPOSITION COMPRISING EXIFONE AND WATER-SOLUBLE POLYMER | Laboratoires Pharmascience (FR) | 1993-01-07 | — | — | EP | claimed |
| US-5093372-A | Used in treatment of dementia, improved solubility, absorption cellulose ethers | FUJISAWA PHARMACEUTICAL CO. INC. (JP) | 1992-03-03 | — | — | US | claimed |
| EP-0315964-A1 | A novel pharmaceutical composition comprising exifone and water-soluble polymer | Laboratoires Pharmascience (FR) | 1989-05-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CYP3A43, NR3C2, CYP3A5 | HDAC1 408/4885SELL 2891/4885SELP 2985/4885 |
| US-20230372312-A1 | Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CYP3A43, NR3C2, CYP3A5 | HDAC1 408/4885SELL 2891/4885SELP 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.